Subtopic Deep Dive
Biliary Tract Cancer Chemotherapy
Research Guide
What is Biliary Tract Cancer Chemotherapy?
Biliary Tract Cancer Chemotherapy evaluates gemcitabine-cisplatin regimens and novel agents for advanced cholangiocarcinoma and gallbladder cancer through phase III trials and biomarker analyses.
Gemcitabine plus cisplatin emerged as the standard first-line therapy following multicentre studies (Okusaka et al., 2010, 729 citations). Gallbladder cancer constitutes 80-95% of biliary tract malignancies with poor prognosis due to late diagnosis (Shaffer and Hundal, 2014, 1038 citations). Over 10 key papers document chemotherapy outcomes in these orphan cancers.
Why It Matters
Gemcitabine-cisplatin improves survival in advanced biliary tract cancers from 4-6 months to 11-12 months, establishing the benchmark regimen (Okusaka et al., 2010). ESMO guidelines recommend this combination for unresectable cases, guiding global clinical practice (Valle et al., 2016, 674 citations). Precision medicine targets like FGFR inhibitors address subsets with actionable mutations, extending progression-free survival (Valle et al., 2017, 630 citations). Pooled analyses confirm gemcitabine's response rates of 20-30% across trials (Eckel and Schmid, 2007, 462 citations).
Key Research Challenges
Limited Phase III Trials
Few randomized controlled trials exist due to low incidence of biliary tract cancers. Okusaka et al. (2010) conducted a comparative multicentre study establishing gemcitabine-cisplatin efficacy in Japan. Pooled analyses highlight inconsistent phase II data (Eckel and Schmid, 2007).
Biomarker Identification
Identifying predictive biomarkers for chemotherapy response remains elusive in cholangiocarcinoma subtypes. Consensus statements note distinct genetic aberrations by anatomic location (Bañales et al., 2016; Brindley et al., 2021). Precision approaches require validated markers (Valle et al., 2017).
Drug Resistance Mechanisms
Rapid development of resistance limits gemcitabine-cisplatin durability in advanced disease. Reviews emphasize dismal prognosis despite standard regimens (Blechacz and Gores, 2008; Blechacz, 2016). Novel agents face barriers in orphan malignancy trials.
Essential Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesús M. Bañales, Vincenzo Cardinale, Guido Carpino et al. · 2016 · Nature Reviews Gastroenterology & Hepatology · 1.3K citations
Gallbladder cancer: epidemiology and outcome
Eldon A. Shaffer, Rajveer Hundal · 2014 · Clinical Epidemiology · 1.0K citations
Gallbladder cancer, though generally considered rare, is the most common malignancy of the biliary tract, accounting for 80%-95% of biliary tract cancers. An early diagnosis is essential as this ma...
Cholangiocarcinoma
Paul J. Brindley, Melinda Bachini, Sumera I. Ilyas et al. · 2021 · Nature Reviews Disease Primers · 768 citations
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has distinct genetic abe...
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
Takuji Okusaka, Kohei Nakachi, Akira Fukutomi et al. · 2010 · British Journal of Cancer · 729 citations
Gemcitabine plus cisplatin combination therapy was found to be effective and well tolerated, suggesting that it could also be a standard regimen for Japanese patients.
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Juan W. Valle, Ivan Borbath, Shahid A. Khan et al. · 2016 · Annals of Oncology · 674 citations
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
Shahid A. Khan, Brian R Davidson, Robert Goldin et al. · 2002 · Gut · 643 citations
2 or 3 studies; D=level 5 evidence or inconsistent or inconclusive studies of any level.
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle, Ángela Lamarca, Lipika Goyal et al. · 2017 · Cancer Discovery · 630 citations
Abstract Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-prognosis and low-incidence cancers, although the incidence of intrahepatic cholangiocarcinoma is...
Reading Guide
Foundational Papers
Start with Shaffer and Hundal (2014, 1038 citations) for gallbladder epidemiology; Okusaka et al. (2010, 729 citations) for gemcitabine-cisplatin efficacy; Eckel and Schmid (2007, 462 citations) for pooled chemotherapy outcomes.
Recent Advances
Study Valle et al. (2016, 674 citations) ESMO guidelines; Valle et al. (2017, 630 citations) precision medicine; Brindley et al. (2021, 768 citations) anatomic subtypes.
Core Methods
Gemcitabine-cisplatin (1000 mg/m² + 25 mg/m² days 1,8 q21); response assessed by RECIST; biomarkers via NGS for FGFR/IDH1 (Valle et al., 2017).
How PapersFlow Helps You Research Biliary Tract Cancer Chemotherapy
Discover & Search
Research Agent uses searchPapers with 'gemcitabine cisplatin biliary tract cancer phase III' to retrieve Okusaka et al. (2010), then citationGraph reveals 700+ citing papers including Valle et al. (2016) ESMO guidelines. exaSearch uncovers Japanese multicentre data; findSimilarPapers links to Eckel and Schmid (2007) pooled analysis.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Okusaka et al. (2010), then runPythonAnalysis with pandas computes pooled response rates across Eckel and Schmid (2007) trials. verifyResponse via CoVe cross-checks claims against Bañales et al. (2016); GRADE grading scores gemcitabine-cisplatin evidence as high-quality from phase III-equivalent studies.
Synthesize & Write
Synthesis Agent detects gaps in post-gemcitabine therapies via contradiction flagging between Okusaka et al. (2010) and Valle et al. (2017), generating Mermaid diagrams of regimen evolution. Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 10-paper bibliographies, and latexCompile for oncologist-ready reviews.
Use Cases
"Extract and meta-analyze survival data from gemcitabine-cisplatin biliary cancer trials"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Okusaka 2010, Eckel 2007) → runPythonAnalysis (pandas survival meta-analysis with HR/CI outputs, matplotlib Kaplan-Meier plots) → GRADE-verified statistical summary.
"Draft ESMO-aligned chemotherapy protocol for advanced cholangiocarcinoma"
Research Agent → citationGraph (Valle 2016) → Synthesis Agent → gap detection → Writing Agent → latexEditText (protocol sections) → latexSyncCitations (10 guidelines papers) → latexCompile (PDF with trial flowcharts via latexGenerateFigure).
"Find open-source analysis code for biliary tract cancer biomarkers"
Research Agent → exaSearch 'cholangiocarcinoma biomarker R code' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (returns FGFR mutation pipelines linked to Valle 2017 precision medicine paper).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ biliary tract chemotherapy papers, chaining searchPapers → citationGraph → runPythonAnalysis for meta-analysis of gemcitabine response rates. DeepScan applies 7-step verification to compare Okusaka et al. (2010) Japanese data against global trials with CoVe checkpoints. Theorizer generates hypotheses on FGFR-targeted sequencing post-gemcitabine failure using Brindley et al. (2021) genetic data.
Frequently Asked Questions
What defines Biliary Tract Cancer Chemotherapy?
It evaluates gemcitabine-cisplatin as first-line for advanced cholangiocarcinoma and gallbladder cancer via phase III trials and biomarkers (Okusaka et al., 2010).
What are standard chemotherapy methods?
Gemcitabine plus cisplatin yields median survival of 11.7 months; 5-FU/gemcitabine alternatives show 20-30% response (Okusaka et al., 2010; Eckel and Schmid, 2007).
What are key papers?
Okusaka et al. (2010, 729 citations) establishes gemcitabine-cisplatin; Valle et al. (2016, 674 citations) provides ESMO guidelines; Shaffer and Hundal (2014, 1038 citations) covers gallbladder epidemiology.
What open problems exist?
Biomarker-driven therapies and resistance mechanisms lack phase III validation; intrahepatic vs. distal cholangiocarcinoma responses differ (Bañales et al., 2016; Valle et al., 2017).
Research Gallbladder and Bile Duct Disorders with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Biliary Tract Cancer Chemotherapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.